MX2013003522A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013003522A
MX2013003522A MX2013003522A MX2013003522A MX2013003522A MX 2013003522 A MX2013003522 A MX 2013003522A MX 2013003522 A MX2013003522 A MX 2013003522A MX 2013003522 A MX2013003522 A MX 2013003522A MX 2013003522 A MX2013003522 A MX 2013003522A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
deferasirox
treatment
relates
iron overload
Prior art date
Application number
MX2013003522A
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013003522(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2013003522A publication Critical patent/MX2013003522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende deferasirox, un procedimiento para preparar tal composición farmacéutica, y su uso en el tratamiento de sobrecarga de hierro crónica. La composición farmacéutica comprende deferasirox nano-dimensionado que tiene un área de superficie y solubilidad mejoradas. También se refiere a un método de tratamiento de sobrecarga de hierro crónica que comprende administrar una composición farmacéutica que comprende deferasirox nano-dimensionado.
MX2013003522A 2010-10-01 2011-09-30 Composicion farmaceutica. MX2013003522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2750MU2010 2010-10-01
PCT/GB2011/001428 WO2012042224A2 (en) 2010-10-01 2011-09-30 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013003522A true MX2013003522A (es) 2013-05-22

Family

ID=44802316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003522A MX2013003522A (es) 2010-10-01 2011-09-30 Composicion farmaceutica.

Country Status (18)

Country Link
US (3) US20140147503A1 (es)
EP (1) EP2621471A2 (es)
JP (1) JP2013538845A (es)
KR (1) KR20140011300A (es)
CN (1) CN103209687A (es)
AP (1) AP3578A (es)
AU (1) AU2011309872B2 (es)
BR (1) BR112013007276A2 (es)
CA (1) CA2812505A1 (es)
EC (1) ECSP13012534A (es)
IL (1) IL225457A (es)
MX (1) MX2013003522A (es)
MY (1) MY165826A (es)
NZ (1) NZ608380A (es)
PE (2) PE20170468A1 (es)
RU (1) RU2589842C2 (es)
WO (1) WO2012042224A2 (es)
ZA (1) ZA201302092B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011326562B2 (en) 2010-11-09 2017-02-23 Cornell University Methods for organ regeneration
EP2916870A1 (en) 2012-11-12 2015-09-16 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
SI2964202T1 (sl) 2013-03-08 2019-02-28 Novartis Ag Peroralne formulacije deferasiroksa
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
ZA201403276B (en) * 2013-05-10 2015-07-29 Cipla Ltd Low dose pharmaceutical composition
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
WO2015140569A1 (en) * 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
CA2989145A1 (en) 2015-06-17 2016-12-22 Dispersol Technologies, Llc Improved formulations of deferasirox and methods of making the same
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
EP3481390A4 (en) * 2016-07-05 2020-03-04 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS
CN107693516B (zh) * 2016-08-08 2020-06-26 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
WO2018187728A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
US20210338657A1 (en) * 2018-08-06 2021-11-04 Brigham Young University Compositions and methods for treating iron overload
BR112022023307A2 (pt) 2020-05-18 2022-12-20 Orexo Ab Composição farmacêutica para entrega de fármacos
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
DE60137362D1 (de) * 2000-11-20 2009-02-26 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US7531351B2 (en) * 2004-06-14 2009-05-12 Probiogen Ag Liquid-gas-phase exposure reactor for cell culturing
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
US20090016359A1 (en) * 2007-07-11 2009-01-15 Samsung Electronics Co., Ltd. System and method for processing high definition video data to be transmitted over a wireless medium
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090142395A1 (en) * 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Also Published As

Publication number Publication date
WO2012042224A8 (en) 2013-04-11
US20160324831A1 (en) 2016-11-10
IL225457A (en) 2017-04-30
AU2011309872A1 (en) 2013-04-11
EP2621471A2 (en) 2013-08-07
PE20170468A1 (es) 2017-04-26
ECSP13012534A (es) 2013-10-31
NZ608380A (en) 2014-10-31
IL225457A0 (en) 2013-06-27
AP3578A (en) 2016-02-08
AU2011309872B2 (en) 2014-09-04
US20180311216A1 (en) 2018-11-01
PE20140166A1 (es) 2014-02-17
BR112013007276A2 (pt) 2016-06-14
MY165826A (en) 2018-05-17
ZA201302092B (en) 2013-11-27
RU2013120275A (ru) 2014-11-20
WO2012042224A3 (en) 2012-08-09
JP2013538845A (ja) 2013-10-17
KR20140011300A (ko) 2014-01-28
RU2589842C2 (ru) 2016-07-10
CN103209687A (zh) 2013-07-17
US20140147503A1 (en) 2014-05-29
WO2012042224A2 (en) 2012-04-05
AP2013006785A0 (en) 2013-04-30
CA2812505A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
MY165826A (en) Pharmaceutical composition
IN2012DN03312A (es)
WO2014062720A3 (en) Methods of treating cancer
GB201118656D0 (en) New compounds
UA115983C2 (uk) Інгібітори днк-пк
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
SG10201903119QA (en) Polypeptide vaccine
IN2014DN10670A (es)
WO2012038504A3 (en) Breast cancer therapeutics
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
IN2014MN02236A (es)
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX2012001306A (es) Inhibicion de matastasis de tumor.
WO2013040227A3 (en) Therapeutic compounds
EP3133073A3 (en) Inhibitors of iap
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
EP2814491A4 (en) FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
PH12014502065A1 (en) Vesicular formulations
MD4615B1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use